Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ (DCIS) Patient Population at Low-risk of Upgrade to Invasive Carcinoma?

被引：0
|
作者：
Pilewskie, M. [1 ]
Stempel, M. [1 ]
Rosenfeld, H. [1 ]
Eaton, A. [1 ]
Van Zee, K. J. [1 ]
Morrow, M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
下载
收藏
页码：S25 / S26
页数：2
相关论文
共 50 条
  • [41] Upgrade of low grade ductal carcinoma in situ (DCIS): Multimodality approach in a 10-year single institution study
    Chu, A.
    Chang, J. M.
    Moon, W. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Low-risk Ductal Carcinoma In Situ (DCIS) Treated with Breast Conserving Surgery and Radiotherapy: Comparison with Intergroup Study E5194
    Motwani, S. B.
    Galper, S. L.
    Goyal, S.
    Moran, M. S.
    Haffty, B. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S53 - S54
  • [43] Touching Tumor-Infiltrating Lymphocytes in Low Risk Ductal Carcinoma In Situ Detected in a Setting Resembling Active Surveillance Clinical Trials for Low Risk DCIS Correlates with Upgrade to High Grade DCIS
    Zhan, Haiying
    Quinn, Marie
    Peng, Xuan
    Yan, Li
    Khoury, Thaer
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 291 - 291
  • [44] Touching Tumor-Infiltrating Lymphocytes in Low Risk Ductal Carcinoma In Situ Detected in a Setting Resembling Active Surveillance Clinical Trials for Low Risk DCIS Correlates with Upgrade to High Grade DCIS
    Zhan, Haiying
    Quinn, Marie
    Peng, Xuan
    Yan, Li
    Khoury, Thaer
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 291 - 291
  • [45] Is excision alone adequate treatment for low-risk ductal carcinoma-in-situ of the breast?
    Solin, LJ
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1017 - 1019
  • [46] Do Clinical and Pathologic Features of Ductal Carcinoma In Situ (DCIS) Vary with Patient Age? An Analysis of 657 Patients
    Collins, L.
    Schnitt, S.
    Achacoso, N.
    Fletcher, S.
    Nekhlyudov, L.
    Haque, R.
    Quesenberry, C.
    Habel, L.
    LABORATORY INVESTIGATION, 2009, 89 : 35A - 35A
  • [47] Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study
    Williams, Lindsay A.
    Casbas-Hernandez, Patricia
    Nichols, Hazel B.
    Tse, Chiu Kit
    Allott, Emma H.
    Carey, Lisa A.
    Olshan, Andrew F.
    Troester, Melissa A.
    PLOS ONE, 2019, 14 (01):
  • [48] Do Clinical and Pathologic Features of Ductal Carcinoma In Situ (DCIS) Vary with Patient Age? An Analysis of 657 Patients
    Collins, L.
    Schnitt, S.
    Achacoso, N.
    Fletcher, S.
    Nekhlyudov, L.
    Haque, R.
    Quesenberry, C.
    Habel, L.
    MODERN PATHOLOGY, 2009, 22 : 35A - 35A
  • [49] The successful patient-preference design for the LORD-trial to test whether active surveillance for low-risk Ductal Carcinoma In Situ is safe
    Schmitz, R.
    Sondermeijer, C.
    Van der Noort, V.
    Engelhardt, E.
    Gerritsma, M.
    Verschuur, E.
    Van Oirsouw, M.
    Bleiker, E.
    Bijker, N.
    Mann, R.
    Van Duijnhoven, F.
    Wesseling, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S3 - S4
  • [50] DCIS II trial: a randomised trial testing observation (no radiotherapy) against radiotherapy in women with low-risk completely excised oestrogen receptor (ER) positive ductal carcinoma in situ (DCIS) of the breast on adjuvant endocrine therapy
    Yarnold, J
    Bundred, N
    Dewar, J
    George, W
    Haviland, J
    Dawson, C
    Bliss, J
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 : S34 - S35
12345